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Abstract
Background: Development of drug resistance in bacteria causes antibiotic therapies to be less effective and more
costly. Moreover, our understanding of the process remains incomplete. One promising approach to improve our
understanding of how resistance is being acquired is to use whole-genome comparative approaches for detection
of drug resistance-associated mutations.
Results: We present GWAMAR, a tool we have developed for detecting of drug resistance-associated mutations in
bacteria through comparative analysis of whole-genome sequences. The pipeline of GWAMAR comprises several
steps. First, for a set of closely related bacterial genomes, it employs eCAMBer to identify homologous gene families.
Second, based on multiple alignments of the gene families, it identifies mutations among the strains of interest.
Third, it calculates several statistics to identify which mutations are the most associated with drug resistance.
Conclusions: Based on our analysis of two large datasets retrieved from publicly available data for M. tuberculosis,
we identified a set of novel putative drug resistance-associated mutations. As a part of this work, we present also
an application of our tool to detect putative compensatory mutations.
Background
The development of drug resistance in bacteria makes
antibiotics less effective and increases the costs of thera-
pies. This problem has drawn the attention of major
health organizations such as WHO (World Health Organi-
zation), ECDC (European Centre for Disease Prevention
and Control) and CDC (Centers for Disease Control and
Prevention) which monitor and report the epidemics of
drug resistance in the world [1,2].
Over a few decades of research on drug resistance, several
drug-resistance mechanisms have been discovered such as
alteration of a drug’s binding site, reduced accumulation of
a drug, and specialized enzymes to degrade drug molecules
[3]. These mechanisms may be acquired either through
chromosomal mutations or horizontal gene transfer.
There are many mutations reported in various studies
as associated with drug resistance mechanisms. However,
the information is spread throughout the literature and
not easy to access. One attempt to collect the informa-
tion on genetic features associated with drug resistance
into a database is the Antibiotic Drug Resistance Data-
base (ARDB) [4]. However, this database focuses on
genes associated with drug resistance rather than particu-
lar point mutations within them. Another species-specific
database of drug resistance-associated mutations in
M. tuberculosis is the Tuberculosis Drug Resistance
Mutation Database (TBDReaMDB) [5]. This database
provides detailed information on a set of 1230 associa-
tions between drugs and point mutations. Furthermore,
it distinguishes a subset of high-confidence mutations
which were often reported in literature.
The process of acquisition of drug resistance is often
associated with some additional cost, called fitness, which
reduces the general viability of the bacteria [6,7]. How-
ever, this effect may be reversed completely or partially
by secondary mutations, called compensatory mutations
[7,8]. Consequently, the evolutionary process of acquiring
multiple drug resistance happens in a sequence of steps
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rather than simultaneously [9-11]. Thus, in order to bet-
ter understand the process, it is important to identify not
only the primary mutations responsible directly for drug
resistance, but also those secondary mutations allowing
for gradual accumulation of drug resistance.
Since the number of bacterial genomes being
sequenced and publicly available sequencing data grows
rapidly [12], it opens new possibilities for using large-
scale computational approaches for identifying drug
resistance-associated mutations.
In our previous work, we presented an approach to use
whole-genome comparative approach for identification of
drug resistance-associated mutations [13]. We proposed
a new computational scoring scheme, called weighted
support, which uses phylogenetic information for identi-
fying the drug resistance-associated mutations. In order
to test our approach, we used publicly available sequen-
cing data for 100 strains of Staphylococcus aureus and
collected phenotype data from over 70 articles. Our
experiment suggested that weighted support outperforms
other standard measures such as mutual information and
odds ratio.
In the current work, we present GWAMAR, a tool for
identifying of drug resistance-associated mutations
based on comparative analysis of whole-genome
sequences of closely related bacterial strains. This tool is
designed as a pipeline. It first employs eCAMBer, our
previously published tool [14], to identify point muta-
tions among the set of considered genomes. These
mutations constitute the genotype data. Then, GWA-
MAR tries to find the associations between the input
phenotype and genotype data by computing several sta-
tistical scores. As a part of this work, we also designed a
new statistical score, viz tree-generalized hypergeometric
score (TGH).
The rational for incorporating phylogenetic informa-
tion into TGH and weighted support is based on our
observation that subtrees of the phylogenetic tree very
often correspond to geographic locations. Since drug
resistance mutations are subject to evolutionary pressure
caused by the drug treatment they should be indepen-
dent of geographic location and therefore be more
widely distributed over the tree, as opposed to muta-
tions driven by other environmental factors which tend
to rather concentrate in small subtrees.
In order to test our approach, we run GWAMAR on
two large datasets for M. tuberculosis. The first dataset
is prepared for the set of 173 strains with genome
sequences and annotations publicly available in the
PATRIC database [15]. And for this set of strains, we
collected drug resistance information from over 20 pub-
lications. The genotype and phenotype data for the sec-
ond dataset comes from the M. tuberculosis Drug
Resistance Directed Sequencing Database.
Methods
We present details of GWAMAR in this section, includ-
ing the problem setting, the preprocessing of input data
and the computation of the association scores between
the drug resistance phenotypes and point mutations.
Problem setting
We consider a set S of closely related bacterial gen-
omes. Typically, this is a set of strains within the same
species of bacteria.
Then, we represent the available drug resistance infor-
mation as a set of drug-resistance profiles R, where each
drug resistance profile r ∈ R is represented as a vector:
r : S → {S, I,R, ?}.
Here, S, I, R denote that a given strain is known to be
drug susceptible, intermediate-resistant, or resistant,
respectively. Using question mark ?′ we indicate that
the drug resistance status of a strain is unknown. We
call a drug resistance profile complete if it does not con-
tain question marks.
Analogously, we represent the genotype data as a set
of mutationsM, where each mutation m ∈M is repre-
sented as a triple (g, p, v), where g,p,v denote the gene
family identifier, the position of the mutation in its cor-
responding multiple alignment, and the mutation profile,
respectively. The mutation profile is represented as a
vector:
v : S →
∑
∪{?}.
Here Σ denotes the set of amino acides (for protein-
coding genes) or nucleotides (for promoters and rRNA
coding genes). We also assume that Σ contains the gap
‘-’ symbol. Using question mark ?′ we indicate that the
corresponding amino acid or nucleotide is unknown.
Analogously, we call a mutation profile complete if it
does not contain question marks.
It should be noted that potentially multiple mutations
at different positions in the genome may have identical
mutation profiles. Moreover, it may happen that multi-
ple mutations may correspond to the same set of
mutated strains. In that situation the mutations would
essentially carry the same information about the profiles.
Thus, we also introduce an auxiliary concept called bin-
ary mutation profile. Let r ∈ S denote the reference
strain and s ∈ S denote any strain. Then, for a given
mutation profile v its corresponding binary mutation




? if v(s) =?
0 if v(s) = v(r)
1 otherwise
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Analogous to mutation profiles, we call a binary muta-
tion profile complete if it does not contain question
marks.
Finally, we define the aim of the tool as: To produce
an ordered list of associations between the phenotype
and genotype data (represented as drug resistance and
mutation profiles) such that the top-scored associations
are the most likely to be real.
The pipeline of GWAMAR
Figure 1 illustrates the overall design of the tool. Data
preprocessing for GWAMAR consists of several steps
which may be performed by our previously developed
tool, eCAMBer [14]. These preprocessing steps com-
prise:
• download genome sequences of multiple bacterial
strains,
• unification of gene annotations,
• identification of homologous gene families,
• multiple alignments of the gene families (employ-
ing MUSCLE),
• reconstruction of the phylogenetic tree (employing
PHYLIP),
• identification of point mutations based on the mul-
tiple alignments.
The input drug-resistance profiles, typically, are col-
lected from the articles or databases which provide
drug-resistance information for the strains of interest.
The set of identified point mutations, the set of drug-
resistance profiles and and the phylogenetic tree consti-
tute the input for GWAMAR.
In the next step, GWAMAR computes binary muta-
tion profiles for each mutation profile. This step signifi-
cantly reduces the number of genetic profiles to be
scored. Finally, GWAMAR computes several statistical
scores to associate drug-resistance profiles to the muta-
tion profiles, including mutual information, odds ratio,
hypergeometric test, weighted support (which is our
previously published approach [13]), and the tree-gener-
alized hypergeometric score (our new approach here).
Tree-generalized hypergeometric score
As a part of this work we also introduce a new associa-
tion score, called tree-generalized hypergeometric score
(TGH ). This score is a modification of the CCTSWEEP
score introduced in the paper [16]. In this section, we
consider a subset of strains S for which a given drug-
resistance profile r and a binary mutation profile b are
complete, i.e. do not contain question marks. Moreover,
we assume that r does not contain any intermediate-
resistant strains. In all our computational experiments
we transform the intermediate-resistant strains into
resistant strains.
In order to present the formal definition of TGH, we
first define an auxiliary concept called coloring. For a
given tree T , we call a subset c of its nodes a coloring,
if it satisfies the following two conditions:
• each path from a leaf to the root contains at most
one node from c,
• each internal node in c has a sibling node which
does not belong to c.
Here we also introduce a function L which, for each
node ω, returns the set of descendants of the node,
including the node itself. We say these nodes are visible
from ω. Additionally, the function L applied to a color-
ing c returns the union of all nodes visible from nodes
in c.
Let CT denote the set of all colorings of T . Then, for
each complete drug-resistance profile r there exists
exactly one coloring ĉ such that the set of leaves visible
from ĉ equals the set of drug-resistant nodes in r. We
say this coloring is induced by the drug-resistance pro-
file. Analogously, for each complete binary mutation
profile b there is exactly one induced coloring c¯.
Intuitively, the coloring induced by a given complete
drug-resistance profile will contain the set of nodes in
which drug-resistance was acquired (assuming a model
in which drug-resistance cannot be reversed). Analo-
gously, the coloring induced by a given binary mutation
profile will contain the set of nodes in which the muta-
tion was acquired.
Figure 2 (A) presents an example of colorings induced
by a given drug-resistance profile (large red nodes) and a
given binary mutation profile (small orange nodes) for a
flat tree. In that situation the colorings may be interpreted
as independent drawing of balls as in the standard hyper-
geometric distribution model. Knowing this property of
TGH we proposed its name as it generalizes the standard
hypergeometric test in the case of a flat tree. Figure 2 (B)
presents another example of colorings induced by the
same pair of profiles, but for a tree which is not flat. In
this model the dependencies between different strains are
captured by the topology of the tree.
Let us now assume we want to compute the TGH
score for a pair of complete drug-resistance profile r
and complete binary mutation profile b. Let us addition-
ally assume that the size of coloring c¯ induced by b
equals n. Morover, let the number of nodes in coloring
c¯ visible from the coloring ĉ equals k. This value can be
interpreted as the number of times the considered
mutation was acquired not earlier than the resistance
was acquired.
Now, let VT(n) denote the number of colorings of size n:
VT(n) = #{c ∈ CT : |c| = n}
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Figure 1 Schema of the GWAMAR pipeline. For a set of considered bacterial strains, the input data for GWAMAR consists of (i) a set of
mutations; (ii) a set of drug resistance profiles; and (iii) phylogenetic tree for the set of bacterial strains. Typically the set of mutation profiles is
generated using eCAMBer, which is able to download the genome sequences and annotations for the set of bacterial strains, identify point
mutations based on multiple alignments, and reconstruct the phylogenetic tree of the considered bacterial strains. The first step of GWAMAR is
to compute binary mutation profiles for all point mutations. This step significantly reduces the number of genetic profiles considered. Finally,
GWAMAR implements several statistical scores to associate drug resistance profiles with mutation profiles. These include: mutual information,
odds ratio, hypergeometric test, weighted support and tree-generalized hypergeometric score (TGH). As a result, we obtain ordered lists of drug
resistance associations, where the top scored associations are the most likely to be real.
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VT(n) may be interpreted as the total number of bin-
ary mutation profiles for which the induced coloring is
of the same size as for c¯.
Then, let BT, ĉ(k, n) denote the number of colorings of
size n, such that exactly k nodes of that coloring are
visible from nodes of coloring ĉ.
BT,cˆ(k,n) = #{c ∈ CT : |L(cˆ) ∩ c| = k and |c| = n}
Here, the value BT, ĉ(k, n) may be interpreted as the
number of binary mutation profiles such that their
induced coloring has n elements, out of which k is visi-
ble from the nodes in ĉ.
Finally, for the complete drug-resistance profile r and
complete binary mutation profile b, which induce colorings
ĉ and c¯, respectively, we define the TGH score as follows:





Here, we take the negative logarithm to have consis-
tent property for all considered scoring methods, such
that the higher the score the more likely drug-resistance
profile r is associated with binary mutation profile b.
Time complexity
Let D denote the number of drug-resistance profiles
considered. Additionally, let N denote the number of
considered strains and M denote the number of binary
mutation profiles. Finally, let K denote the maximal
number of children of an internal node in the tree.
Then, the time complexity of the algorithms we imple-
mented to compute the hypergeometic score, the
mutual information, odds ratio, and weighted support is
O(D N M ). In order to compute TGH, we implement
a dynamic programing algorithm which computes the
values Bω,ĉ(k, n) for each internal node ω, k and n.
This strategy gives an algorithm with complexity
O(D·N K−1·N2 +D·N·M ). For the brevity of the presen-
tation we skip details of the algorithm.
Results and discussion
We now present and discuss results we obtained applying
GWAMAR on the two datasets we prepared for M.
tuberculosis.
In all the following analyzes we use the set of mutations
classified as high-confidence mutations in Tuberculosis
Drug Resistance Mutation Database (TBDReaMDB) as
our gold standard [5]. In total the database contains 88 of
high-confidence associations spanning 27 genes and six
drugs or drug families: Fluoroquinolones, Ethambutol,
Isoniazid, Pyrazinamide, Rifampicin and Streptomycin.
Mtu173 case study
The first case study is based on the set of 173 fully
sequenced strains of M. tuberculosis with publicly available
data.
The preprocessing steps of preparing the genotype
data were performed using eCAMBer, our previously
Figure 2 Example colorings for the TGH score. (A) an example of coloring ĉ induced by a given drug-resistance profile (large red nodes) and
coloring c¯ induced by a given binary mutation profile (small orange nodes) for a flat tree. In this example |cˆ| = 5, |c¯| = 3 and |L(cˆ) ∩ c¯| = 3.
(B) another example of colorings ĉ and c¯ induced by the same pair of profiles but for a different tree. In this example |cˆ| = 3, |c¯| = 2 and
|L(cˆ) ∩ c¯| = 2|
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published tool to support comparative analysis of multi-
ple bacterial strains [13].
In particular, first, we used eCAMBer to download the
genome sequences and annotations from the PATRIC
database [15]. Next, we applied eCAMBer to unify the
genome annotations of protein-coding genes and to
identify the clusters of genes with high sequence similar-
ity. Then, for the subset of 4379 such identified gene
clusters with genes present in at least 90% of the strains,
we computed multiple alignments using MUSCLE [17].
The multiple alignments were computed for amino-acid
sequences of protein-coding genes, as well as nucleotide
sequences of their promoter regions, and rRNA genes.
Finally, based on the computed multiple alignments, we
identified 118913 non-synonymous point mutations.
The set of identified point mutations constituted the
input genotype data for GWAMAR.
The input phenotype data was collected from over 20
publications issued together with the fully sequenced
genomes. Additional file 1 shows the drug-resistance sta-
tus of the strains retrieved from literature together with
references. Based on the drug-resistance information col-
lected for Ciprofloxacin and Ofloxacin, we introduced a
new drug-resistance profile for Fluoroquinolones. A
strain is categorized as susceptible to Fluoroquinolones if
it was susceptible to at least one of the drugs, but
not resistant to any of them. Similarly, a strain was
categorized as resistant to Fluoroquinolones if it was
resistant to at least one of the drugs, but not susceptible
to any of them. If none of the cases was satisfied for a
strain, then the drug-resistance status of the strain was
categorized as unknown. We restrict further analysis to
the set of six drugs or drug families: Fluoroquinolones,
Ethambutol, Isoniazid, Pyrazinamide, Rifampicin and
Streptomycin.
The input phylogenetic tree was reconstructed using
the maximum-likelihood approach implemented in the
PHYLIP package. As an input for the tool we used the
set of all the identified mutations concatenated into one
multiple alignment file. Additional file 2 presents the
reconstructed phylogenetic tree.
Table 1 presents the list of top 20 associations ordered
according to TGH score. In the set of 20 top-scoring
associations, 15 are present in the TBDReaMDB database
and 13 of them are categorized as high-confidence muta-
tions. A closer look at the mutations which are not pre-
sent in TBDReaMDB revealed that some of them can be
supported by literature. In particular, mutation E504G/D
in embB has recently been reported as associated with
resistance to Ethambutol [18]. Similarly, the mutation
T539I has already been associated with resistance to
Fluoroquinolones [19].
Literature search did not provide us any additional
support for the remaining three mutations (A505T in
Table 1 20 top-scoring associations between drug-resistance profiles and point mutations in the case study on 173
fully sequenced M.tuberculosis strains.
drug name gene id gene name mutation all h.c. TGH
Fluoroquinolones Rv0006 gyrA D94G/A/H/N/Y Y Y 14.1843430424
Isoniazid Rv1908c katG S315T/G/N Y Y 9.04507605888
Rifampicin Rv0667 rpoB S450L Y Y 8.60191917013
Streptomycin Rv0682 rpsL K43R Y Y 8.32303955124
Ethambutol Rv3795 embB M306I/V/L Y Y 8.24966301883
Isoniazid Rv1483 fabG1 C-15T Y Y 5.8445976648
Rifampicin Rv0667 rpoB D435F/V/Y/G/A Y Y 5.0402225732
Streptomycin Rv0682 rpsL K88R/M Y Y 4.16354931535
Ethambutol Rv3795 embB E504G/D N N 3.33103155053
Pyrazinamide Rv2043c pncA W68L Y Y 2.7080502011
Pyrazinamide Rv2043c pncA H51P Y Y 2.7080502011
Rifampicin Rv0667 rpoB H445D/Y/R Y Y 2.52993515037
Streptomycin Rvnr01 rrs G1108C N N 1.71691080314
Ethambutol Rv3795 embB D1024N Y N 1.68763546921
Ethambutol Rv3795 embB D869G N N 1.68763546921
Ethambutol Rv3795 embB A505T N N 1.68763546921
Fluoroquinolones Rv0005 gyrB N538T Y Y 1.68478734968
Fluoroquinolones Rv0006 gyrA S91P Y Y 1.68478734968
Fluoroquinolones Rv0005 gyrB T539I N N 1.68478734968
Streptomycin Rvnr01 rrs A1401G Y N 1.28846347057
Each row corresponds to one association, whereas the consecutive columns describe: drug name, gene identifier, gene name, mutation, association presence in
the TBDReaMDB database, status indicating if the association is categorized as high confidence in TBDReaMDB, TGH score.
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embB, D869G in embB and G1108C in rrs), which
haven’t been reported in TBDReaMDB. These mutations
may potentially be false positives or real drug-resistance-
associated mutations.
Mtu_broad case study
The second case study, mtu_broad, is based on the data
available in the Broad Institute database http://www.
broadinstitute.org/annotation/genome/mtb_drug_resis-
tance.1/. This database contains provides sequencing data
and drug-resistance information for 1398 strains of
M. tuberculosis. However, it should be noted that only
genes of interest were sequenced. Table 2 presents the
list of 28 sequenced genes for each strain. Additionally 12
promoter sequences were sequenced. In total, this data-
base contains 1069 mutations (non-synonymous amino-
acid changes or nucleotide changes in promoters).
Similar to the previous case study, based on the drug-
resistance information available in the database for
Ciprofloxacin, Ofloxacin, Levofloxacin and Moxifloxacin,
we introduced a new drug-resistance profile for Fluoro-
quinolones. A strain was categorized as susceptible to
Fluoroquinolones if it was susceptible to at least one of
the drugs, but not resistant to any of them. Similarly, a
strain was categorized as resistant to Fluoroquinolones
if it was resistant to at least one of the drugs, but not
susceptible to any of them. If none of the cases was
satisfied for a strain, then the drug-resistance status of
the strain was categorized as unknown. We restrict
further analysis to the set of six drugs or drug families:
Fluoroquinolones, Ethambutol, Isoniazid, Pyrazinamide,
Rifampicin and Streptomycin.
Similarly, as in the previous case study, the phyloge-
netic tree was reconstructed using the maximum-likeli-
hood approach implemented in the PHYLIP package. As
an input for the tool we used the set of all available
mutations concatenated into one multiple alignment file.
Table 3 presents the list of the top 20 associations
ordered according to TGH score. In the set of 20 top-
scoring associations, 19 are present in TBDReaMDB and
15 of them are categorized as high-confidence mutations.
A closer look at the mutation D89G/N, which is not
present in TBDReaMDB, reveals that the mutation has
recently been associated with resistance to Fluoroquino-
lones [20].
The set of associations provides some additional sup-
port for the four mutations which were present in
TBDReaMDB, but not categorized as high-confidence.
Table 2 List of sequenced genes and promoters available in the mtu_broad dataset.
gene id gene name description promoter sequenced?
Rv0005 gyrB DNA gyrase subunit B yes
Rv0006 gyrA DNA gyrase subunit A yes
Rv0341 iniB isoniazid inductible gene protein yes
Rv0342 iniA isoniazid inductible gene protein yes
Rv0343 iniC isoniazid inductible gene protein yes
Rv0667 rpoB DNA-directed RNA polymerase beta chain yes
Rv0682 rpsL 30S ribosomal protein S12 yes
Rv1483 fabG1 3-oxoacyl-[acyl-carrier protein] reductase yes
Rv1484 inhA NADH-dependent enoyl-[acyl-carrier-protein] reductase yes
Rv1694 tlyA cytotoxin–haemolysin no
Rv1854c ndh NADH dehydrogenase yes
Rv1908c katG catalase-peroxidase-peroxynitritase T no
Rv2043c pncA pyrazinamidase/nicotinamidas yes
Rv2245 kasA 3-oxoacyl-[acyl-carrier protein] synthase 1 no
Rv2427Ac oxyR’ hypothetical protein no
Rv2428 ahpC alkyl hydroperoxide reductase C protein yes
Rv2764c thyA thymidylate synthase yes
Rv2764c ddl D-alanine-D-alanine ligase ddlA no
Rv3423c alr alanine racemase no
Rv3793 embC membrane indolylacetylinositol arabinosyltransferase yes
Rv3794 embA membrane indolylacetylinositol arabinosyltransferase yes
Rv3795 embB membrane indolylacetylinositol arabinosyltransferase yes
Rv3854c ethA monooxygenase yes
Rv3919c gid glucose-inhibited division protein B yes
Rvnr01 rrs ribosomal RNA 16S no
Rvnr02 rrl ribosomal RNA 23S no
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Assessment of accuracy
Here we use the two datasets described above to assess
the accuracy of the various association scores, viz: mutual
information, odds ratio, hypergeometric score, weighted
support and TGH. The CCTSWEEP software might con-
tain some bugs and did not produce correct output. Its
authors had not responded to our queries in time. So we
omitted it from our experiments.
As our gold standard we use the set of 88 drug-resis-
tance associations classified as high-confidence in the
Tuberculosis Drug Resistance Mutation Database
(TBDReaMDB) [5].
In both case studies, as the set of positives, we assume
the subset of high-confidence mutations present in
TBDReaMDB, which are also present in the genotype
data. This is the set of mutations which may be potentially
detected using the available datasets. There are 39 and 75
of such associations for the mtu173 and mtu_broad data-
sets, respectively. The set of negatives is constructed by
random sampling from the whole set of identified putative
associations except for the associations which are classified
as positives. The number of sampled negatives equals the
total number of mutations present in genes which has at
least one high-confidence mutation. We use this approach
in order to significantly reduce the probability of classify-
ing as negatives associations which are real but not present
in the database.
Figure 3 presents precision and recall curves for differ-
ent association scores. Consistently, results on both data-
sets suggest that tree-aware scores outperform tree-
ignorant scores.
Rifampicin resistance and compensatory mutations
It is commonly known that Rifampicin resistance in
M. tuberculosis gets acquired by point mutations within
the RRDR region which corresponds to the Rifampicin
binding spot [21]. However, these mutations are often
associated with deleterious effect on bacteria fitness [22].
This effect may be potentially reversed by compensatory
mutations. Recently, three new papers have been released,
focusing on identifying putative compensatory mutations
within rpoA, rpoB and rpoC genes [23-25].
Figure 4 presents the distribution of the putative com-
pensatory mutations identified in these recent studies,
put together with mutations identified based on our two
case studies.
Interestingly, several mutations identified by our
approach have also been reported in at least one of the
papers [23-25].
• rpoA: G31S/A
• rpoB: P45S/L, L731P, E761D, R827C, H835P/R
• rpoC: G332R/S, V431M, G433C/S, V483G/A,
W484G, I491T/V, L527V, N698K, A734V
Table 3 20 top-scoring associations between drug-resistance profiles and point mutations in the case study for 1398
partially sequenced M.tuberculosis strains.
drug name gene id gene name mutation all h.c. TGH
Fluoroquinolones Rv0006 gyrA D94A/G/N/Y/H Y Y 129.754964792
Fluoroquinolones Rv0006 gyrA A90G/V Y Y 41.8967753922
Streptomycin Rv0682 rpsL K43R Y Y 31.005838239
Isoniazid Rv1908c katG S315T/S/G/N/I/R Y Y 27.1918713598
Ethambutol Rv3795 embB Q497P/R/K/H Y Y 17.1681425414
Streptomycin Rv0682 rpsL K88T/R/Q/M Y Y 16.2806822989
Fluoroquinolones Rv0005 gyrB N538K/T/D/S Y Y 12.6368065275
Rifampicin Rv0667 rpoB H445P/D/R/Y/L/N/Q Y Y 12.627849397
Streptomycin Rvnr01 rrs A1401G Y N 9.60726487825
Pyrazinamide Rv2043c pncA T135P/A Y N 9.35766011848
Streptomycin Rvnr01 rrs A514C Y Y 8.96892262877
Rifampicin Rv0667 rpoB D435Y/V/H/G/A/N Y Y 7.63431166207
Fluoroquinolones Rv0006 gyrA S91P Y Y 7.57935978224
Pyrazinamide Rv2043c pncA T-11C/G Y Y 6.76727069266
Ethambutol Rv3795 embB G406S/D/A/C Y Y 6.32500852932
Fluoroquinolones Rv0006 gyrA D89G/N N N 6.26814578901
Pyrazinamide Rv2043c pncA L120P/R Y N 6.11085770664
Streptomycin Rvnr01 rrs C517T Y Y 5.16411345885
Ethambutol Rv3795 embB D328Y/G/H Y N 5.07901609928
Pyrazinamide Rv2043c pncA V139G/A/M/L Y Y 5.05727324518
This dataset is provided by The Broad Institute. Each row corresponds to one association, whereas the consecutive columns describe: drug name, gene identifier,
gene name, mutation, association presence in the TBDReaMDB database, status indicating if the association is categorized as high confidence in TBDReaMDB,
TGH score.
Wozniak et al. BMC Genomics 2014, 15(Suppl 10):S10
http://www.biomedcentral.com/1471-2164/15/S10/S10
Page 8 of 11
Additional file 3 contains the detailed table with the
complete list of putative compensatory mutations.
Conclusion
In this work we presented GWAMAR, a tool we have
developed for identifying of drug-resistance associated
mutations based on comparative analysis of whole-gen-
ome sequences in bacterial strains.
The tool is designed as an automatic pipeline which
employs eCAMBer, our previously published tool [14],
for preprocessing of data. This preprocessing includes:
(i) download of genome sequences and gene annotations,
Figure 3 Comparison of accuracy. Precision-recall curves for comparison of different association scores implemented in GWAMAR. Left panel
presents results for the mtu173 dataset; right for the mtu_broad dataset. Numbers present in the square brackets display the Area Under the
Curve (AUC) for the scores. In both case studies tree-aware statistics (weighted support and TGH) achieve better performance the the tree-
ignorant statistics.
Figure 4 Compensatory mutations. Distribution of putative compensatory mutations with the rpoA, rpoB and rpoC genes. Position of each
mutation is indicated by a vertical line.
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(ii) unification of gene annotations among the set of con-
sidered strains, (iii) identification of gene families, (iv)
computation of multiple alignments and identification of
point mutations which constitute the input genotype data.
GWAMAR implements various statistical methods–
such as mutual information, odds ratio, hypergeometric
test and weighted support [13]– to associate the drug-
resistance phenotypes with point mutations. As a part of
this work, we also present tree-generalized hypergeo-
metric score (TGH) – a new statistical score.
In order to test our approach, we prepared two data-
sets for M. tuberuclosis. Results of both case studies sug-
gest that tree-aware methods (weighted support and
TGH) perform better than methods which do not incor-
porate phylogenetic information. This result supports
also our corollary from our previous paper about
weighted support [13]. Employing GWAMAR on the
two datasets, we identified novel mutations putatively
associated with drug-resistance.
Finally, despite some promising results, the presented
tool has some limitations. First, it does not take into
account or predict epistatic interactions between muta-
tions. Second, it only takes into account genomic changes
ignoring levels of gene expression. Thirdly, it provides
putative in-silico associations which should be subjected to
further investigation in wet lab experiments.
Availability
The GWAMAR software, input data and results of the
case study experiments are available at the website:
http://bioputer.mimuw.edu.pl/gwamar.
Additional material
Additional file 1: Drug-resistance information for 173 strains of M.
tuberculosis. Drug-resistance information collected from literature for 173
strains of M. tuberculosis.
Additional file 2: Phylogenetic tree for 173 strains of M. tuberculosis.
Phylogenetic tree reconstructed using the maximum-likelihood method
implemented in the PHYLIP for 173 strains of M. tuberculosis.
Additional file 3: Putative compensatory mutations. Complete list of
putative compensatory mutations identified in three different studies and
our two datasets.
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